

### YOUR SMILE. OUR VISION.



Long successful operating history – founded in 1972 and listed on ASX in 1985 and Australia's largest dental manufacturer



SDI researches, develops, manufactures and markets specialist dental restorative products, focusing on filling materials and tooth whitening products



SDI sells to 100+ countries on all continents and with sales teams and distribution in Australia, Brazil, Europe and North America

#### AGENDA

- o FY18 highlights
- Product categories
- Key geographies
- Financial performance
- Strategy and outlook




YOUR SMILE. **OUR** VISION.



#### FY18 HIGHLIGHTS


- NPAT up 1.5% to \$5.7m
- Strong second half result with 2H18 up 27% on pcp
- O Sales increased 0.5% to \$74.5m
- Non-amalgam sales rose 8.6%, a faster pace than the market
- Aesthetic sales up 9.3% in local currency (up 10.5% in AUD)
- Product margins increased by 1.1% to 61.1%, due to product and market sales mix, and Australian manufacturing efficiencies
- O Full year fully franked dividends of 2.5 cents up 8.7%
- O Debt reduction of \$1.9m
- FDA registration approval granted to market Riva Star in the USA as a dental desensitiser
- Health Canada approval to market Riva Star as an anti-caries agent

#### Sales v EBITDA




# DIVIDENDS GROWTH AND NO NET DEBT

#### **Net Debt & Free Cashflow**



#### **EPS & DPS**



- Net cash position with strong free cashflow
- Increased dividend and payout ratio reflective of balance sheet strength and the Board's confidence

CREATED BY SDI





#### PRODUCT CATEGORIES







CREATED BY SE

/hitening

#### **AESTHETICS DRIVING GROWTH**

- Aesthetics sales performed strongly, up 9.3% in local currency (up 10.5% in AUD)
- Whitening sales grew 4.3% in local currency (up 5% in AUD) in 2H due to strong Pola brand
- Continued decline in amalgam sales, down 12.7% in local currency (down 12.9% in AUD)

Product	Growth in	Growth in	Total
<b>Category Sales</b>	Local Currency	AUD	AUD Sales
Aesthetics	9.3%	10.5%	38.9%
Equipment	(2.5%)	(4.2%)	8.3%
Whitening	1.0%	2.0%	26.7%
Amalgam	(12.7%)	(12.9%)	26.1%





#### KEY GEOGRAPHIES





#### SALES BY BUSINESS UNIT

- Australian business unit grew sales by 4.9%.
   When adjusted for Brazil, export sales grew by 0.2%.
- O Brazilian sales decreased by 9.0%. When adjusted for the redirection of export sales to Australia, Brazil's domestic sales increased by 0.8%.
- Europe increased by 0.6%:
  - Under performing sales to the Turkish market.
- North American sales decreased by 1.7%:
  - Major distributor undergoing restructure

Sales by	Growth in	Growth in	Total
<b>Business Units</b>	Local Currency	AUD	AUD Sales
Australian Sales*	4.9%	2.9%	35.1%
North American	(1.7%)	(4.6%)	24.1%
Europe	0.6%	6.9%	33.2%
Brazil	(9.0%)	(15.0%)	7.6%
TOTAL	0.5%	0.6%	100.0%

<sup>\*</sup>Australian business unit sales includes direct exports to other markets



#### **GEOGRAPHICAL SALES**


North America FY18 \$18.0m -4.6% Europe FY18 \$27.9m +9.0%

Middle East/Africa FY18 \$6.4m -5.9%

South America FY18 \$9.2m -6.1%

APAC FY18 \$13.0m +0.2%

#### Sales by geographical location A\$(m)



CREATED BY SDI





# FINANCIAL PERFORMANCE



YOUR SMILE. **OUR** VISION.

### PROFIT & LOSS

Profit & Loss (\$'000)	FY18	FY17	Change
Revenue			
Sales revenue	74,535	74,066	1%
Cost of goods sold	(28,966)	(29,625)	(2%)
Gross profit	45,569	44,441	3%
Gross margin	61%	60%	
Expenses			
Selling and administration expenses	(34,231)	(32,829)	4%
Research and development costs	(1,253)	(921)	36%
Other expenses	(1,976)	(2,600)	(24%)
Profit before tax	8,145	8,191	(1%)
Tax expense	(2,484)	(2,615)	(5%)
Net profit after tax	5,661	5,576	2%
Depreciation & Amortisation	(3,868)	(4,094)	(6%)
Net interest expense	(135)	(210)	(36%)
EBITDA	12,148	12,495	(3%)

- 0.6% sales increase in local currency
- Strong sales in Aesthetics and Whitening products were offset by Amalgam sales (down 12.9% in AUD)
- Gross margin increased by 1.1% due to product mix and production efficiencies
- Operating expenses increased by 2.1% in local currencies
- Expenses driven by:
- additional investment in promotional and research expenditure
- increase compliance costs
- reduction in currency losses

### BALANCE SHEET

Balance sheet (\$'000)	FY18	FY17	Change
Assets			
Cash and cash equivalents	8,246	5,754	43%
Trade and other receivables	16,225	15,451	5%
Inventories	14,558	17,135	(15%)
Prepayments	750	818	(8%)
Other receivables	885	1,124	(21%)
Property, plant and equipment	17,569	18,121	(3%)
Intangibles	23,657	22,859	3%
Total assets	81,890	81,262	1%
Liabilities			
Trade and other payables	3,960	4,551	(13%)
Borrowings	2,214	4,137	(46%)
Derivative financial instruments	-	62	(100%)
Provision for income tax	182	248	(27%)
Employee benefits	3,546	3,715	(5%)
Deferred tax liability	2,437	2,206	10%
Total liabilities	12,339	14,919	(17%)
Net assets	69,551	66,343	5%

- Cash holdings for the year increased by \$2.5 million and debt falling by \$1.9 million
- \$2.7 million
  reduction in
  inventory from
  improved
  manufacturing
  processes and
  larger sales in May
  and June
- Receivable days have increased due to stronger sales in May and June
- Increased R & D expenditure, continuing the investment in new product development
- Continued debt reduction program

### **CASH FLOW**

Cashflow statement (\$'000)	FY18	FY17	Change
Receipts from customers	74,000	73,110	1%
Payments to suppliers and employees	(60,264)	(60,454)	(0%)
Other revenue	36	100	(64%)
Interest and other finance costs paid	(163)	(219)	(26%)
Income taxes paid	(2,319)	(3,165)	(27%)
Net cash from operating activities	11,290	9,372	20%
Payments for PP&E	(1,824)	(2,678)	(32%)
Payments for intangibles	(2,346)	(2,920)	(20%)
Proceeds from disposal of PP&E	43	275	(84%)
Net cash used for investing activities	(4,127)	(5,323)	(22%)
Cash flows used in financing activities	(4,776)	(4,208)	13%
Cash & cash equivalents - end of period	8,246	5,754	43%

- Strong free cash flow
- O Reduction of R & D expenditure capitalized
- Continued debt reduction





## STRATEGY AND OUTLOOK





#### RESEARCH, INNOVATION, RESULTS

- 4 new products being developed for launch at the International Dental Show (IDS) – March 2019
- Whitening
  - Pola Tray
- Aesthetics
  - Adhesive
  - Cement
  - Flowable composite

- 1 − 2 new products per year to drive growth
- Concentrating on categories that deliver high sales margins
- Building on SDI's worldleading technical expertise, particularly in glass ionomers and tooth whitening.
- Very focused R+D teams collaborating closely with researchers, universities and innovation centres globally

- Riva star focus on public health programs to minimise adverse restorative procedures
- Key study with Dental Health Services Victoria showing positive results



CREATED BY SDI



#### OUTLOOK

- The most significant product release for FY19 will be a new Pola whitening tray
- Riva Star gaining traction in North America
- Growth opportunity in developing markets as demand for quality dentistry increases
- Research expenditure increase on innovation such as amalgam alternatives
- Expanding manufacturing in Brazil. No material investment in PPE. Will lead to saving costs
- In FY19, we expect continued sales growth in non-amalgam products, offset by ongoing weakness in the market for amalgam
- PPE to increase to \$3m to automate packing, filling line and the Riva capsulation line





#### DISCLAIMER

LIMITED TO, ANY ASSUMPTIONS OR EXPECTATIONS SET OUT IN THIS PRESENTATION).

THIS PRESENTATION CONTAINS SUMMARY INFORMATION ABOUT SDI LIMITED (SDI) AND ITS SUBSIDIARIES AND THEIR ACTIVITIES. THE INFORMATION IN THIS PRESENTATION DOES NOT PURPORT TO BE COMPLETE. IT SHOULD BE READ IN CONJUNCTION WITH SDI'S OTHER PERIODIC AND CONTINUOUS DISCLOSURE ANNOUNCEMENTS LODGED WITH THE AUSTRALIAN SECURITIES EXCHANGE, WHICH ARE AVAILABLE AT WWW.ASX.COM.AU.

THE INFORMATION CONTAINED IN THIS PRESENTATION IS NOT INVESTMENT OR FINANCIAL PRODUCT ADVICE AND HAS BEEN PREPARED WITHOUT TAKING INTO ACCOUNT THE INVESTMENT OBJECTIVES, FINANCIAL SITUATION OR PARTICULAR NEEDS OF ANY PARTICULAR PERSON. BEFORE MAKING AN INVESTMENT DECISION, INVESTORS SHOULD CONSIDER THE APPROPRIATENESS OF THE INFORMATION HAVING REGARD TO THEIR OWN INVESTMENT OBJECTIVES, FINANCIAL SITUATION AND NEEDS AND SEEK INDEPENDENT PROFESSIONAL ADVICE APPROPRIATE TO THEIR JURISDICTION AND CIRCUMSTANCES.

TO THE EXTENT PERMITTED BY LAW, NO RESPONSIBILITY FOR ANY LOSS ARISING IN ANY WAY FROM ANYONE ACTING OR REFRAINING FROM ACTING AS A RESULT OF THIS INFORMATION IS ACCEPTED BY SDI, ANY OF ITS RELATED BODIES CORPORATE OR ITS DIRECTORS, OFFICERS, EMPLOYEES, PROFESSIONAL ADVISORS AND AGENTS (RELATED PARTIES). NO REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, IS MADE BY ANY PERSON, INCLUDING SDI AND ITS RELATED PARTIES, AS TO THE FAIRNESS, ACCURACY, COMPLETENESS OR CORRECTNESS OF THE INFORMATION, OPINIONS AND CONCLUSIONS CONTAINED IN THIS PRESENTATION.

AN INVESTMENT IN SDI SECURITIES IS SUBJECT TO INVESTMENT AND OTHER KNOWN AND UNKNOWN RISKS, SOME OF WHICH ARE BEYOND THE CONTROL OF SDI OR ITS DIRECTORS. SDI DOES NOT GUARANTEE ANY PARTICULAR RATE OF RETURN OR THE PERFORMANCE OF SDI SECURITIES.

PAST PERFORMANCE INFORMATION GIVEN IN THIS PRESENTATION IS GIVEN FOR ILLUSTRATIVE PURPOSES ONLY AND SHOULD NOT BE RELIED UPON AS (AND IS NOT) AN INDICATION OF FUTURE PERFORMANCE.

THIS PRESENTATION CONTAINS CERTAIN FORWARD-LOOKING STATEMENTS WITH RESPECT TO THE FINANCIAL CONDITION, RESULTS OF OPERATIONS AND BUSINESS OF SDI AND ASSOCIATED ENTITIES OF SDI AND CERTAIN PLANS AND OBJECTIVES OF THE MANAGEMENT OF SDI. FORWARD-LOOKING STATEMENTS CAN BE IDENTIFIED BY THE USE OF FORWARD-LOOKING TERMINOLOGY, INCLUDING, WITHOUT LIMITATION, THE TERMS "BELIEVES", "ESTIMATES", "ANTICIPATES", "EXPECTS", "PREDICTS", "INTENDS", "PLANS", "GOALS", "TARGETS", "AIMS", "OUTLOOK", "GUIDANCE", "FORECASTS", "MAY", "WILL", "WOULD", "COULD" OR "SHOULD" OR, IN EACH CASE, THEIR NEGATIVE OR OTHER VARIATIONS OR COMPARABLE TERMINOLOGY. THESE FORWARD-LOOKING STATEMENTS INCLUDE ALL MATTERS THAT ARE NOT HISTORICAL FACTS. SUCH FORWARD-LOOKING STATEMENTS INVOLVE KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND OTHER FACTORS WHICH BECAUSE OF THEIR NATURE MAY CAUSE THE ACTUAL RESULTS OR PERFORMANCE OF SDI TO BE MATERIALLY DIFFERENT FROM THE RESULTS OR PERFORMANCE EXPRESSED OR IMPLIED BY SUCH FORWARD-LOOKING STATEMENTS.

SUCH FORWARD-LOOKING STATEMENTS ARE BASED ON NUMEROUS ASSUMPTIONS REGARDING SDI'S PRESENT AND FUTURE BUSINESS STRATEGIES AND THE POLITICAL, REGULATORY AND ECONOMIC ENVIRONMENT IN WHICH SDI WILL OPERATE IN THE FUTURE, WHICH MAY NOT BE REASONABLE, AND ARE NOT GUARANTEES OR PREDICTIONS OF FUTURE PERFORMANCE. NO REPRESENTATION OR WARRANTY IS MADE THAT ANY OF THESE STATEMENTS OR FORECASTS (EXPRESS OR IMPLIED) WILL COME TO PASS OR THAT ANY FORECAST RESULT WILL BE ACHIEVED. FORWARD-LOOKING STATEMENTS SPEAK ONLY AS AT THE DATE OF THIS PRESENTATION AND TO THE FULL EXTENT PERMITTED BY LAW, SDI AND ITS RELATED PARTIES DISCLAIM ANY OBLIGATION OR UNDERTAKING TO RELEASE ANY UPDATES OR REVISIONS TO INFORMATION TO REFLECT ANY CHANGE IN ANY OF THE INFORMATION CONTAINED IN THIS PRESENTATION (INCLUDING, BUT NOT

STATUTORY PROFIT IS PREPARED IN ACCORDANCE WITH THE CORPORATIONS ACT 2001 AND THE AUSTRALIAN ACCOUNTING STANDARDS, WHICH COMPLY WITH THE INTERNATIONAL FINANCIAL REPORTING STANDARDS (IFRS). UNDERLYING PROFIT IS CATEGORISED AS NON-IFRS FINANCIAL INFORMATION AND THEREFORE HAS BEEN PRESENTED IN COMPLIANCE WITH AUSTRALIAN SECURITIES AND INVESTMENTS COMMISSION REGULATORY GUIDE 230 – DISCLOSING NON-IFRS INFORMATION, ISSUED IN DECEMBER 2011.

ALL FIGURES IN THIS PRESENTATION ARE A\$ UNLESS STATED OTHERWISE AND ALL MARKET SHARES ARE ESTIMATES ONLY. A NUMBER OF FIGURES, AMOUNTS, PERCENTAGES, ESTIMATES, CALCULATIONS OF VALUE AND FRACTIONS ARE SUBJECT TO THE EFFECT OF ROUNDING. ACCORDINGLY, THE ACTUAL CALCULATIONS OF THESE FIGURES MAY DIFFER FROM FIGURES SET OUT IN THIS PRESENTATION.